seviteronel
Seviteronel is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017, seviteronel received fast-track designation for breast cancer as well. — Wikipedia
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2011 (NCT02012920)
Timeline
Indications
Mechanism of action
- Androgen ReceptorANTAGONIST
Androgen Receptor antagonist
- Cytochrome P450 17A1INHIBITOR
Cytochrome P450 17A1 inhibitor
Chemistry & pharmacology
SMILES
CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1- Mol. weight
- 399.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSeviteronel ↗
- ChEMBLCHEMBL3264610 ↗
Also known as
- seviteronel
- seviteronel
- seviteronel
- vt-464
- vt-464
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04947189 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2021 | University of New South Wales |
| NCT03600467 | Phase 2 | Aug 13, 2018 | University of New South Wales |
| NCT02580448 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Innocrin Pharmaceutical, Sponsor GmbH |
| NCT02445976 | Phase 2 | May 1, 2015 | Innocrin Pharmaceutical, Prostate Cancer Clinical Trials Consortium, Prostate Cancer Foundation, Sponsor GmbH |
| NCT02361086 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Innocrin Pharmaceutical |
| NCT02130700 | Phase 2 | Apr 1, 2014 | Innocrin Pharmaceutical, National Cancer Institute (NCI) |
| NCT02012920 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2011 | Innocrin Pharmaceutical |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innocrin Pharmaceutical | For profit | 5 | 5 | 1 | 2011 |
| Sponsor GmbH | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of New South Wales | Academic/Hospital | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| Prostate Cancer Clinical Trials Consortium | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2015 |